Galmed (GLMD) reports aramchol 3–4x cell death vs enzalutamide alone
Galmed announces first results from prostate oncology studies showing aramchol delivers a 3–4 fold increase in cell death versus enzalutamide (XTANDI®) alone in prostate cancer models.